Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

Front Cardiovasc Med. 2021 May 5:8:679124. doi: 10.3389/fcvm.2021.679124. eCollection 2021.

¹ Department of Endocrinology, Shenzhen Longhua District Central Hospital, Shenzhen, China.
² Department of Nephrology, Shenzhen Hospital of Beijing University of Chinese Medicine, Shenzhen, China.
³ Class 3, Clinical Medicine, Grade 2019, The Second Clinical Medical College, Southern Medical University, Guangzhou, China.
⁴ Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.

No abstract available

Keywords: Heart failure; RAS blockers; SGLT2 inhibitors; cardiorenal events; type 2 diabetes mellitus.